NASDAQ · TALS

Talaris Therapeutics, Inc.

Healthcare · Biotechnology

$2.72

Down-$0.02 (-0.73%)

Updated Sep 13, 2026, 1:19 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 116.44M
P/E ratio: -13.97
Dividend yield: 0.00%
52-week range: — – —
Volume: 303.48K
Avg. volume: 143.21K

Price performance

TALS price history

1M range · 0 trading sessions · Daily adjusted prices

Data unavailable

The requested market data was not found.

Latest TALS news

The latest Smart Investors Daily articles mentioning TALS.

No results

No recent SID articles mention TALS.

Latest TALS news

The latest Smart Investors Daily articles mentioning TALS.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

TALS research

Overview

Company profile and research snapshot.

Company profile

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: —
Implied upside: —
Analysts: —

TALS recent ratings
Date	Firm	Rating	Target
Apr 17, 2023	HC Wainwright & Co.	Neutral	—
Feb 23, 2023	Morgan Stanley	Equal-Weight	—
Jan 30, 2023	HC Wainwright & Co.	Buy	—
Oct 24, 2022	HC Wainwright & Co.	Buy	—
Oct 20, 2022	SVB Leerink	Market Perform	—

Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Oct 18, 2023

Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Shift Technologies, Inc. (NASDAQ: SFT) shares rose 74.4% to $0.1878 in pre-market trading. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares gained 45% to $2.45 in pre-market trading after gaining around 4% on Tuesday. RVL Pharmaceuticals plc (NASDAQ: RVLP) shares climbed 41.2% to $0.0720 in pre-market trading after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12, the company received a delisting notice from the Listing Qualifications Department of Nasdaq Stock Market LLC. Intelligent Bio Solutions Inc. (NASDAQ: INBS) rose 28.6% to $0.3912 in pre-market trading. Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) shares rose 14.4% to $0.3498 in pre-market trading after jumping 15% on Tuesday. Advent Technologies Holdings, Inc. (NASDAQ: ADN) gained 14.3% to $0.4799 in pre-market trading. Micromobility.com Inc. (NASDAQ: ...

GlobeNewswire Inc. · Oct 17, 2023

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By